Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 20/20 | 0.68 |
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 0.68 |
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL1394547 | 0.97 | CHRM3 (0.64) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL29355152 | 0.81 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL140648 | 0.81 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL524037 | 0.81 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL140647 | 0.81 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL16781068 | 0.80 | CHRM3 (0.97) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL29504618 | 0.80 | CHRM3 (0.97) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL3682092 | 0.80 | CHRM3 (0.97) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL3682091 | 0.80 | CHRM3 (0.97) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL146665 | 0.79 | CHRM3 (0.94) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963307-A1 | 3- (4- { [4-(4-{ [3-(3, 3-DIMETHYL-1-PIPERIDINYL) PROPYL[0XY] PHENYL) -1-PIPERIDINYL CARBONYL }-1-NAPHTHALENYL) PROPANOIC OR PROPENOIC ACID AS H1 AND H3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY AND/OR ALLERGIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-09-03 | — | — | EP | disclosed |
| EP-1957512-A1 | 17.BETA.-FLUOROMETHOXYCARBONYL-ANDROST-4-EN-3-ONE COMPOUNDS WITH A 17.ALPHA.-CARBONATE SUBSTITUENT | GLAXO GROUP LIMITED (GB) | 2008-08-20 | — | — | EP | disclosed |
| EP-1906964-A1 | PIPERAZINONE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR ANTAGONISTS AND/OR INVERSE AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-04-09 | — | — | EP | disclosed |
| WO-2008000777-A2 | PHENYL- PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | GLAXO GROUP LIMITED (GB) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007071691-A1 | 3- (4-{ [4-(4-{ [3-(3, 3-DIMETHYL-1-PIPERIDINYL) PROPYL] 0XY} PHENYL) -1-PIPERIDINYL] CARBONYL }-1-NAPHTHALENYL) PROPANOIC OR PROPENOIC ACID AS H1 AND H3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY AND/OR ALLERGIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007059949-A1 | TWO NOVEL SALTS OF THE N, N' -BIS [9- (3,4-DIHYDROXY-5- (2-ETHYL-2H-TETRAZOL-5-YL) TETRAHYDROFURAN-2-YL) -2- (2- (1-METHYL-1H-IMIDAZOL-4-YL) ETHYLAMINO) -9H-PURIN-6-YL] CYCLOHEXYL-1,4-DIAMINE ADENOSINE A2A AGONIST AS ANTI-INFLAMMATORY AGENTS | GLAXO GROUP LIMITED (GB) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007057152-A1 | 17.BETA.-FLUOROMETHOXYCARBONYL-ANDROST-4-EN-3-ONE COMPOUNDS WITH A 17.ALPHA.-CARBONATE SUBSTITUENT | GLAXO GROUP LIMITED (GB) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007009741-A1 | PIPERAZINONE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR ANTAGONISTS AND/OR INVERSE AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |